Mucosal Impedance and Eosinophilic Esophagitis

Overview

About this study

Do patients with eosinophilic esophagitis have baseline increased esophageal mucosal impedance? And will treatment that reverses esophageal eosinophilia in patients, correct abnormalities in mucosal impedance?

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion criteria:

Adults ages 18-90 undergoing clinically indicated upper endoscopy
Patients with EoE, defined as dysphagia with histologic finding of greater than or equal to 15 eosinophils per high powered field on esophageal biopsy despite at least 6 weeks of twice daily proton pump inhibitor therapy
Patients undergoing clinically indicated upper endoscopy for indications other than dysphagia or GERD with normal appearing esophageal mucosa.

Exclusion criteria:

Medical conditions such as severe heart or lung disease that preclude safe performance of endoscopy
Patients with conditions known to be associated with esophageal eosinophilia, including Crohn’s disease, Churg-Strauss, achalasia, and hypereosinophilic syndrome
Inability to read due to: Blindness, cognitive dysfunction, or English language illiteracy

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status
Rochester, Minn. Mayo Clinic principal investigator David Katzka, M.D.	Closed for enrollment

Mayo Clinic Location

Status

Rochester, Minn.

Mayo Clinic principal investigator

David Katzka, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Clinical Trials